Finance
Hepatitis drug maker reports loss of $0.50 per share
Published in Hepatitis Weekly, September 13th, 2004
"We are pleased with the progress we made during the second quarter as we continue to advance the clinical development of our lead Hepatitis C and Hepatitis B programs," said Kleanthis G. Xanthopoulos, PhD, Anadys' president and CEO.
"Meanwhile, we continue to harvest additional promising drug candidates utilizing our integrated drug discovery and development platform, while leveraging these capabilities in discovery collaborations with pharmaceutical and biotechnology companies such as Roche and Daiichi.
"We hope to build on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-09-13)
More Articles from Hepatitis Weekly
- Adverse Drug Effects
Peginterferon may cause sustained cryoglobulinemia-related vasculitis - Cancer Diagnosis
Serum complexes bolster the detection of primary liver cancer - Carcinogenesis
Key proteins decline in patients with hepatitis C-related liver cancer - Chronic Hepatitis C
Patients with high hepatitis C virus loads benefit from long-term therapy - Diagnostics
Dried blood samples are useful for analyzing hepatitis B virus DNA - Acute Liver Failure
Indomethacin reduces intracranial pressure in ALF patients - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
